Kidney as an important metabolic organ for recombinant human insulin- like growth factor-I

Research Communications in Molecular Pathology and Pharmacology

Volumn 96, Issue 3, 1997, Pages 267-276

  Tanaka, Yoshio ^a   Kitao, Kaori ^c   Hata, Takehisa ^c   Kimura, Toshikiro ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ANIMAL TISSUE; ARTICLE; GENETIC RECOMBINATION; GLOMERULUS FILTRATION RATE; HORMONE RESISTANCE; HORMONE RESPONSE; HYPOGLYCEMIA; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; URINARY EXCRETION;

ANIMALS; GLOMERULAR FILTRATION RATE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 0030758532     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bach, M.A., Chin, E. and Bondy, C.A. (1994). The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 79: 1040-1045.
2. Ballard, F.J., Knowles, P.E., Walton, P.E., Edson, K., Owens, P.C., Mohler, M.A. and Ferraiolo, B.L. (1991). Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats. J. Endocrinol. 128:197-204.
3. Caro, J.F., Poulos, J., Ittoop, O., Pories, W.J., Flickinger, E.G. and Sinha, M.K. (1988). Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerated, and fetal rat liver. J. Clin. Invest. 81: 976-981.
4. DÍercole, A.J., Decedue, C.J., Furlanetto, R.W., Underwood, L.E. and Van Wyk J.J. (1977). Evidence that somatomedin-C is degraded by the kidney and inhibits insulin degradation. Endocrinology 101: 577-586.
5. Froesch, E.R., Schmid, Chr., Schwander, J. and Zapf, J. (1985). Actions of insulin-like growth factors. Ann. Rev. Physiol. 47: 443-467.
6. Gibbons, J.A., Luo, Z.P., Hannon, E.R., Braeckman, R.A. and Young, J.D. (1995). Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureter-ligated rats. J. Pharmacol. Exp. Ther. 272: 119-125.
7. Gutierrez J., Parrizas, M., Maestro, M.A., Navarro, I. and Plisetskaya, E.M. (1995). Insulin and IGF-I binding and tyrosine kinase activity in fish heart. J. Endocrinol. 146: 35-44.
8. Husdan, H. and Rapoport, A. (1968). Estimation of creatinine by the jaffe reaction: a comparison of three methods. Clin. Chem. 14: 222-238.
9. Katz, A.I. and Rubenstein, A.H. (1973). Metabolism of proinsulin, insulin, and C-peptide in the rat. J. Clin. Invest. 52: 1113-1121.
10. Kim, D.C., Sugiyama, Y., Fuwa, T., Sakamoto, S., Iga, T. and Hanano, M. (1989). Kinetic analysis of the elimination process of human epidermal growth factor (hEGF) in rats. Biochem. Pharmacol. 38: 241-249.
11. Kimura, T., Kanzaki, Y., Matsumoto, Y., Mandai, M., Kurosaki, Y. and Nakayama, T. (1994). Disposition of recombinant human insulin-like growth factor-I in normal and hypophysectomized rats. Biol. Pharm. Bull. 17: 310-315.
12. Kitabchi, A.E. and Stenz, F.B. (1972). Degradation of insulin and proinsulin by various organ homogenates of rat. Diabetes 21: 1091-1101.
13. Klapper, D.G., Svoboda, M.E. and Van Wyk, J.J. (1983). Sequence analysis of somatomedin-C confirmation of identity with insulin-like growth factor I. Endocrinology 112: 2215-2217.
14. Kohama, Y., Okabe, M., Tujikawa, K., Oka, H., Teramoto, T., Kayamori, Y., Itoh, M. and Mimura, T. (1992). Preparation of biologically active and site specifically recombinant human insulin-like growth factor-I. Chem. Pharm. Bull. 40: 808-810.
15. Kozuya, H., Matsuura, N., Sakamoto, M., Makino, H., Sakamoto, Y., Kadowaki, T., Suzuki, Y., Kobayashi, M., Akazawa, Y., Nomura, M., Yoshimasa, Y., Kasuga, M., Goji, K., Nagataki, S., Oyasu, H. and Imura, H. (1993). Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42: 696-705.
16. Lund, S., Flyvbjerg, A., Holman, G.D., Larsen, F.S., Pedersen, O. and Schmitz, O. (1994). Comparative effects of IGF-I and insulin on the glucose transporter system in rat muscle. Am. J. Physiol.267: E461-E466.
17. Matsuo, N., Yasukura, M., Etoh, Y., Sasaki, N., Okada, S., Tajiri, H., Nose, O. and Nishi, Y. (1992). Effects of FK780 (recombinant hIGF-I) on growth hormone insensitivity syndromes. Jpn. Pharmacol. Ther. 20: 2027-2035.
18. Mosthaf, L., Grako, K., Dull, T.J., Coussens, L., Ullrich, A. and McClain, D.A. (1990). Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 9: 2409-2413.
19. Parrizas, M., Maestro, M.A., Banos, N., Navarro, I., Planas, J. and Gutierrez, J. (1995). Insulin/IGF-I binding ratio in skeletal and cardiac muscles of vertebrates: a phylogenetic approach. Am. J. Physiol. 269: R1370-R1377.
20. Saito, Y., Yamada, H., Niwa, M. and Ueda, I. (1987). Production and isolation of recombinant somatomedin C. J. Biochem. 101: 123-134.
21. Schoenle, E., Zapf, J., Humbel, R.E. and Froesch, E.R. (1982) Insulin-like growth factor stimulates growth in hypophysectomized rats. Nature 296: 252-53.
22. Smith, H.W., Finkelstein, N., Aliminosa, L., Crawford, B. and Graeber, M. (1945). The renal clearance of substituted hippuric acid derivatives and other aromatic acids in dog and man. J. Clin. Invest. 24: 388-404.
23. Stump, D.C., Kieckens, L., Cock, de F. and Collen, D. (1987). Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. J. Pharmacol. Exp. Ther. 242: 245-250.
24. Suzuki, S., Hashimoto, K., Asada, T., Nakanishi, S., Horiai, H. and Niwa, M. (1987). The measurement of plasma IGF-I/ somatomedin-C by radioimmunoassay method. Clin. Pharmacol. (Japan) 35: 853-858.
25. Tait, J.F. (1963). Review: the use of isotopic steroids for the measurement of production rates in vivo. J. Clin. Endocrinol. Metab. 23: 1285-1297.
26. Takakura, Y., Mahato, R. I., Nishikawa, M. and Hashida, M. (1996). Control of pharmacokinetic profiles of drug-macromolecule conjugates. Adv. Drug Delivery Rev. 19: 377-399.
27. Tanaka, H. and Tokiwa, T. (1990). Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res. 50: 6615-6619.
28. Tokazewski-chen, S.A., Marafino, Jr, B.J. and Stebbing, N. (1983). Effects of nephrectomy on the pharmacokinetics of various cloned human interferons in the rat. J. Pharmacol. Exp. Ther. 227: 9-15.
29. Turnheim, K. and Waldhaeusl, W.K. (1988). Essentials of insulin pharmacokinetics. Wien. Klin. Wochenschr. 100: 65-72.
30. Zapf, J., Schoenle, E. and Froesch, E.R. (1978). Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. Eur. J. Biochem. 87: 85-296.